Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.
Betül OranRima M SalibaRohtesh S MehtaAmin M AlousiDavid MarinBen C ValdezJulianne ChenQaiser BashirStefan O CiureaAmanda L OlsonChitra HosingPartow KebriaeiKaty RezvaniElizabeth J ShpallRichard E ChamplinBorje S AnderssonUday R PopatPublished in: Cancer (2021)
A myeloablative, fractionated busulfan regimen reduces relapse and improves survival without increasing NRM in older patients with AML and myelodysplastic syndrome.